Clinical trial of a new beta-receptor blocking agent, tolamolol, in angina pectoris.

The effect of a new beta-adrenergic blocking agent tolamolol, has been examined in a double-blind cross-over study in 18 patients suffering from angina pectoris. After a run-in period of four weeks, during which the patients received placebo, there were two periods each of four weeks when either tolamolol (100-200 mg three times daily) or placebo was given. The patients underwent a standardized exercise test at the end of each treatment period. Tolamolol caused a significant decrease in anginal attacks and the patients' consumption of nitroglycerin was reduced compared both to the run-in and placebo periods. There was an increase in the capacity for physical work, but it was significant only in comparison with the run-in period. Heart rate and blood pressure were significantly reduced at rest and at work during treatment with tolamolol. There were no side effects of treatment with tolamolol. [ABSTRACT FROM AUTHOR]